Meridia (sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events

Audience: Primary Care, Consumers ISSUE: Abbott Laboratories and FDA notified healthcare professionals and patients about the voluntary withdrawal of Meridia (sibutramine), an obesity drug, from the U.S. market because of clinical trial data…



No related posts.